Loew D
Arzt für Pharmakologie/Klin. Pharmakologie, Universität Frankfurt, Wuppertal.
Fortschr Med. 1997 Jan 30;115(3):40-2.
Since the nineteen-sixties, L-Tryptophan has been used with success to treat depressive states and sleep disorders. When, in 1989, the substance was suspected of causing severe adverse reactions (EMS), approval for its use was initially suspended. It has since been shown that the undesired side effects were due not to L-Tryptophan itself, but to contaminations of the basic substance, and the suspension of approval was therefore lifted. In September 1996, L-Tryptophan was re-introduced onto the market as Ardeytropin. The present paper takes a look at the substance L-Tryptophan and discusses in particular its biochemical significance and its biokinetics/pharmacokinetics. The pharmacological basis for the use of L-Tryptophan to treat sleep disorders and depression is examined.
自20世纪60年代以来，L-色氨酸已成功用于治疗抑郁状态和睡眠障碍。1989年，该物质被怀疑会引起严重不良反应（嗜酸性粒细胞增多性肌痛综合征），其使用批准最初被暂停。后来发现，不良副作用并非由L-色氨酸本身引起，而是由基础物质的污染所致，因此批准的暂停被解除。1996年9月，L-色氨酸作为Ardeytropin重新投放市场。本文研究了L-色氨酸这种物质，并特别讨论了其生化意义及其生物动力学/药代动力学。还考察了使用L-色氨酸治疗睡眠障碍和抑郁症的药理学基础。
